Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HighTide TherapeuticsHTTIF 9 3-Year Revenue Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 767 Biotechnology companies, HighTide Therapeutics ranks worse than 130377.97% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
HighTide Therapeutics 3-Year Revenue Growth Rate Related Terms
HTTIF vs VRTX, REGN, MRNA: 3-Year Revenue Growth Rate Comparison
For the Biotechnology subindustry, HighTide Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HighTide Therapeutics 3-Year Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where HighTide Therapeutics's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 0.00% mean?
HighTide Therapeutics (HTTIF) has a 3-Year Revenue Growth Rate of 0.00% as of Dec. 2025. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for HighTide Therapeutics and its competitors. According to the industry distribution chart, HighTide Therapeutics ranks #999999 out of 767 companies in the Biotechnology industry.
Is HighTide Therapeutics' 3-Year Revenue Growth Rate too high?
HighTide Therapeutics' current 3-Year Revenue Growth Rate is 0.00%. Based on the distribution chart, HighTide Therapeutics ranks #999999 out of 767 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HighTide Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' 3-Year Revenue Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #999999 out of 767 companies for 3-Year Revenue Growth Rate. This places HighTide Therapeutics in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 3.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.30, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for HighTide Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HighTide Therapeutics's current 3-Year Revenue Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current 3-Year Revenue Growth Rate of 0.00%. The current 3-Year Revenue Growth Rate is 0.00%. HighTide Therapeutics' overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current 3-Year Revenue Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
9GF Score
Get the complete analysis for HTTIF
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTTIF has been successfully added to your 
